Beta-2-microglobulin (beta2-m) has been proposed as a marker of middle molecules to assess one aspect of the efficacy of dialysis. Until now, few data have been published about extra renal (metabolic) clearance and generation rates of beta2-microglobulin, which are necessary for calculation of total clearance and mass removal of beta2-m in hemodialysis patients. We have developed a simple method to derive extra renal clearance and generation rates of beta2-m by measuring the pre and post dialysis blood concentrations of beta2-m using kinetic modeling. Ten stable hemodialysis patients were included in this study. Pre and post dialysis concentrations of beta2-m were measured during dialysis with low flux dialyzers (F6 HPS) and after 10 days switching to high flux dialyzers (F60S or Superflux). With a validated two pool model, the generation rate of beta2-m can be determined if extra renal clearance is known. Assuming the generation rate of beta2-m to be constant in each patient, the computer reiterated the calculation of extra renal clearance until the calculated generation rate was equal for both the low flux and the high flux dialyzer. Extra renal clearance was found to be between 1.97 and 4.11 ml/min (average, 3.2 ml/min). Generation rate was found in a rather narrow range between 1.63 and 2.56 mg/kg per day (average, 2.09 mg/kg per day). There was no correlation between extra renal clearance and generation rates. With this simple method, extra renal clearance and generation rates of beta2-m can be determined using data by switching hemodialysis patients from impermeable to permeable membranes.

Download full-text PDF

Source
http://dx.doi.org/10.1097/00002480-200111000-00011DOI Listing

Publication Analysis

Top Keywords

extra renal
32
renal clearance
28
clearance generation
20
generation rate
20
hemodialysis patients
16
generation rates
16
clearance
9
generation
9
renal
8
beta2-m
8

Similar Publications

Introduction: Endobronchial metastases (EBMs) are rare, with primary tumours predominantly of breast, renal, and colorectal origin. Bronchoscopy is the diagnostic gold standard, with histological confirmation through immunohistochemical study.

Cases: We presented three cases of EBMs, one secondary to colorectal cancer and two associated with renal tumours.

View Article and Find Full Text PDF

Systemic lupus erythematosus (SLE) is a complex autoimmune disease with a number of immunological aberrations in the mechanisms of innate and adaptive immune responses. Spontaneous and induced mouse models of the disease have contributed significantly to the advancement in lupus treatments. The involvement of humanized models, engrafted with lupus patients' immune cells, represented the possibility to study the development of SLE.

View Article and Find Full Text PDF

Although the phase III SUNLIGHT trial has demonstrated the survival benefit of the addition of bevacizumab (Bmab) to trifluridine/thymidine phosphorylase inhibitor (FTD/TPI), neutropenia, which frequently occurs during FDT/TPI + Bmab therapy, is a concern for clinicians. As TPI is excreted by the kidneys, the risk of adverse events is likely to be high in patients with an impaired renal function. This study aimed to investigate the relationship between renal impairment and the incidence of chemotherapy-induced neutropenia during FTD/TPI + Bmab therapy using real-world data.

View Article and Find Full Text PDF

Rationale: Infection-related glomerulonephritis (IRGN) is an immune-mediated glomerulonephritis caused by extra-renal infectious diseases. There has been an important shift in epidemiology in recent years, with a significant proportion of adults affected. The incidence of IRGN is higher amongst Indigenous populations and especially in those with multiple comorbidities.

View Article and Find Full Text PDF
Article Synopsis
  • Diabetic nephropathy is closely linked to persistent high blood sugar levels, resulting in both kidney and heart vascular issues, particularly in type 1 diabetes, where genetics play a significant role in risk.
  • Extensive research, including genome-wide association studies (GWAS), has identified the angiotensin I-converting enzyme (ACE) gene as a major factor in susceptibility and prognosis for diabetic nephropathy.
  • Despite various studies identifying genetic variants like ACE I/D polymorphism and others, no major gene has been conclusively linked, and the effects observed remain relatively modest.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!